Fibroscan: A new noninvasive method for evaluation of liver dysfunction in Turner syndrome

European Journal of Clinical Investigation

Volumn 41, Issue 2, 2011, Pages 183-188

  Messina, Maria Francesca ^a   Squadrito, Giovanni ^b   Valenzise, Mariella ^a   Maimone, Sergio ^b   Iannelli, Stefania ^a   Arrigo, Teresa ^a   Cacciola, Irene ^b   Civa, Rosi ^a   D'agata, Vittoria ^a   Raimondo, Giovanni ^b   De Luca, Filippo ^a  

^a Departments of Pediatrics   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Liver dysfunction; Liver enzymes; Metabolic syndrome; Transient elastography; Turner syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMIL TRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRANSFERASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; BODY MASS; CHEMICAL ANALYSIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; ELASTOGRAPHY; HUMAN; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER INJURY; METABOLIC SYNDROME X; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; PUBERTY; RISK FACTOR; SCHOOL CHILD; TRANSIENT ELASTOGRAPHY; TURNER SYNDROME;

ADOLESCENT; ADULT; CHILD; CROSS-SECTIONAL STUDIES; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; LIVER DISEASES; MALE; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TURNER SYNDROME; YOUNG ADULT;

EID: 78651301349     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02397.x     Document Type: Article

References (27)

1. Gravholt CH. Epidemiological, endocrine and metabolic features in Turner syndrome. Eur J Endocrinol 2004;151:657-87.
2. Salerno M, Di Maio S, Gasparino N, Rizzo M, Ferri P, Vajro P. Liver abnormalities in Turner syndrome. Eur J Endocrinol 1999;158:618-23.
3. Albareda MM, Gallego A, Enriquez J, Rodriguez JL, Webb SM. Biochemical liver abnormalities in Turner's syndrome. Eur J Gastroenterol Hepatol 1999;11:1037-9.
4. Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol 1998;51:147-58.
5. McHutchison J, Poynard T, Afdhal N; International Fibrosis Group Meeting Partecipants. Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group. Clin Gastroenterol Hepatol 2006;4:1214-20.
6. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999;45 (Suppl. 4):IV1-11.
7. Persico M, Palmentieri B, Secchione R, Torella R, de SI. Diagnosis of chronic liver disease: reproducibility and validation of liver biopsy. Am J Gastroenterol 2002;97:491-2.
8. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008;48:835-47.
9. de Ledinghen V, Vergniol J. Transient elastography (FibroScan). Gastroenterol Clin Bio 2008;32:58-67.
10. Haffner SM, Gonzales C, Miettinen H, Kennedy E, Stern MP. A prospective analysis of the HOMA model. Diabetes Care 1996;19:1138-41.
11. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573-7.
12. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
13. Koulouri O, Ostberg J, Conway GS. Liver dysfunction in Turner's syndrome: prevalence, natural history and effect of exogenous oestrogen. Clin Endocrinol 2008;69:306-10.
14. El-Mansoury M, Berntorp K, Bryman I, Hanson C, Innala E, Karlsson A et al. Elevated liver enzymes in Turner syndrome during a 5-year follow-up study. Clin Endocrinol 2008;68:485-90.
15. NIH Consensus Statement on Management of Hepatitis C. Hepatology 2002; 36: S3-20.
16. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the group of epidemiology of the French association for the study of the liver (AFEF). Hepatology 2000;32:477-81.
17. Afdhal NH. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood test? Hepatology 2003;37:972-4.
18. Lucidarme D, Foucher J, Le Bail B, Vergniol J, Castera L, Duburque C et al. Factors of accuracy of transient elastography (Fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009;49:1083-9.
19. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55:403-8.
20. Maimone S, Calvaruso V, Pleguezuelo M, Squadrito G, Amaddeo G, Jacobs M et al. An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers. J Viral Hepat 2009;16:769-74.
21. Non-invasive methods for the evaluation of hepatic fibrosis/cirrhosis 2006. Available at:.
22. Castera L, Pinzani M. Non-invasive assessment of liver fibrosis: are we ready? Lancet 2010;375:1419-20.
23. Wasniewska M, Bergamaschi R, Matarazzo P, Predieri B, Bertelloni S, Petri A et al. Increased liver enzymes and hormonal therapies in girls and adolescents with Turner syndrome. J Endocrinol Invest 2005;28:720-6.
24. Roulot D, Degott C, Chazouilleres O, Oberti F, Cales P, Carbonelles N et al. Vascular involvement of the liver in Turner's syndrome. Hepatology 2004;39:239-47.
25. Lanthier N, Horsmans Y, Leclercq IA. The metabolic syndrome: how it may influence hepatic stellate cell activation and hepatic fibrosis. Curr Opin Clin Nutr Metab Care 2009;12:404-11.
26. Fracanzani AL, Valenti AL, Bugianesi E, Andreolotti M, Colli A, Vanni E et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008;48(3):792-8.
27. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al. Nonalcoholic fatty liver disease, steatohepatitis and the metabolic syndrome. Hepatology 2003;37:917-23.